Loading patent…
AssigneesMillennium Pharmaceuticals, Inc., Board of Regents, The University of Texas System
InventorsNatalia Iartchouk, Mark Ayers, Jeffrey Brown, Robert Bast, Karen Lu, Gordon Mills
Estimating the term…
The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.
A method for determining whether paclitaxel can be used to reduce the growth of a tumor, comprising the steps of:
A method for determining whether paclitaxel can be used to reduce the growth of a tumor, comprising the steps of:
A method for determining whether treatment with paclitaxel should be continued in a cancer patient, comprising the steps of:
An isolated nucleic acid molecule comprising a nucleotide sequence of SEQ ID NOs:1-88.
An isolated polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence of SEQ ID NOs:1-88.
Dependencies are inferred from the claim text.